PerCP/Cyanine5.5 anti-mouse CD62L Antibody

Pricing & Availability
Clone
MEL-14 (See other available formats)
Regulatory Status
RUO
Other Names
L-selectin, LECAM-1, Ly-22, LAM-1, MEL-14
Isotype
Rat IgG2a, κ
MEL-14_PerCPCy55_CD62L_Antibody_101618.png
C57BL/6 mouse splenocytes were stained with CD3e APC and CD62L (clone MEL-14) PerCP/Cyanine5.5 (left), or rat IgG2a, κ PerCP/Cyanine5.5 isotype control (right).
  • MEL-14_PerCPCy55_CD62L_Antibody_101618.png
    C57BL/6 mouse splenocytes were stained with CD3e APC and CD62L (clone MEL-14) PerCP/Cyanine5.5 (left), or rat IgG2a, κ PerCP/Cyanine5.5 isotype control (right).
Compare all formats See PerCP/Cyanine5.5 spectral data
Cat # Size Price Quantity Check Availability
104431 25 µg $118.00
Check Availability


Need larger quantities of this item?
Request Bulk Quote
104432 100 µg $323.00
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD62L is a 74-95 kD glycoprotein also known as L-selectin, LECAM-1, Ly-22, LAM-1, and MEL-14. It is a member of the selectin family and is expressed on the majority of B and naïve T cells, a subset of memory T cells, monocytes, granulocytes, most thymocytes, and a subset of NK cells. CD62L is important in lymphocyte homing to high endothelial venules (HEV) in peripheral lymph nodes and leukocyte "rolling" on activated endothelium. CD62L also contributes to neutrophil emigration at inflammatory sites. CD62L is rapidly shed from lymphocytes and neutrophils upon cellular activation and the expression levels of CD62L (in conjunction with other markers) have been used to distinguish naïve, effector, and memory T cells. CD62L has been reported to interact with CD34, GlyCAM-1, and MAdCAM-1.

Technical data sheet

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
C3H/eb mouse B lymphoma 38C-13
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with PerCP/Cyanine5.5 under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is = 0.25 µg per 106 cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

* PerCP/Cyanine5.5 has a maximum absorption of 482 nm and a maximum emission of 690 nm.

Application Notes

Additional reported applications (for the relevant formats) include: immunoprecipitation1-3, complement-dependent cytotoxicity4, in vivo and in vitro blocking of adhesion1-3,5, and immunohistochemical staining of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections6. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. Nos. 104457-104462).

Application References

(PubMed link indicates BioLegend citation)
  1. Gallatin WM, et al. 1983. Nature 304:30. (IP, Block)
  2. Siegelman MH, et al. 1990. Cell 61:611. (IP, Block)
  3. Lewinsohn DM, et al. 1987. J. Immunol. 138:4313. (IP, Block)
  4. Iwabuchi K, et al. 1991. Immunobiology 182:161. (CMCD)
  5. Pizcueta P, et al. 1994. Am. J. Pathol. 145:461.
  6. Reichert RA, et al. 1986. J. Immunol. 136:3535. (IHC, FC)
  7. Olver S, et al. 2006. Cancer Res. 66:571.
  8. Fukushima A, et al. 2006. Invest. Ophthalmol. Vis. Sci. 47:657. PubMed
  9. Benson MJ, et al. 2007. J. Exp. Med. doi:10.1084/jem.20070719. (FC) PubMed
  10. Chappaz S, et al. 2007. Blood doi:10.1182/blood-2007-02-074245. (FC) PubMed
  11. Lee JW, et al. 2006. Nature Immunol. 8:181.
  12. Shigeta A, et al. 2008. Blood 112:4915 (FC) PubMed
  13. de Vries VC, et al. 2009. Am. J. Transplant. 9:2270 PubMed
Product Citations
  1. Strickley JD, et al. 2019. Nature. 575:519. PubMed
  2. Lin D, et al. 2016. Cancer Res . 76: 3179 - 3188. PubMed
  3. Zhao Z, et al. 2022. Adv Sci (Weinh). 9:e2201293. PubMed
  4. Lefebvre MN, et al. 2021. Cell Rep. 37:109956. PubMed
  5. Israelow B, et al. 2020. bioRxiv. . PubMed
  6. Hirata Y et al. 2018. Cell stem cell. 22(3):445-453 . PubMed
  7. Cui N, et al. 2017. Chin Med J (Engl). 10.4103/0366-6999.205850. PubMed
  8. Wang D, et al. 2018. Immunity. 48:659. PubMed
  9. Liu QZ, et al. 2018. Front Immunol. 1.131944444. PubMed
  10. Wabitsch S, et al. 2021. Cell Mol Gastroenterol Hepatol. 12:1166. PubMed
  11. Diao L, et al. 2022. iScience. 25:105511. PubMed
  12. Delacher M, et al. 2021. Immunity. 54(4):702-720.e17. PubMed
  13. Ma C, et al. 2018. Science. 360:eaan5931. PubMed
  14. Lu SX, et al. 2021. Cell. . PubMed
  15. Bartleson JM, et al. 2020. Nat Immunol. 1384:21. PubMed
  16. van der Veeken J et al. 2019. Immunity. 50(5):1202-1217 . PubMed
  17. Ma C, et al. 2016. Nature. 531:253-257. PubMed
  18. Ruf B, et al. 2021. Cancer Immunol Res. 9:1024. PubMed
  19. Huang Z, et al. 2021. Nat Commun. 12:145. PubMed
  20. Anger-Góra N, et al. 2021. Oncol Lett. 22:582. PubMed
  21. Rashid MH, et al. 2021. Oncol Rep. 45:1171. PubMed
  22. Holz LE et al. 2018. Cell reports. 25(1):68-79 . PubMed
  23. Wang YT, et al. 2020. Nat Microbiol. 0.397222222. PubMed
  24. Li J, et al. 2022. Nat Commun. 13:4032. PubMed
  25. Evgin L, et al. 2022. Sci Transl Med. 14:eabn2231. PubMed
  26. Rive CM, et al. 2022. Mol Ther Methods Clin Dev. 26:4. PubMed
  27. Wang Y, et al. 2021. Nat Commun. 12:4964. PubMed
  28. Ben-Yehuda H, et al. 2021. Mol Neurodegener. 16:39. PubMed
  29. Gong N, et al. 2020. Nat Nanotechnol. 1.35625. PubMed
  30. Bajaña S, et al. 2022. iScience. 25:103732. PubMed
  31. Basu J, et al. 2022. Commun Biol. 5:84. PubMed
  32. Dudeck J, et al. 2021. Immunity. 54(3):468-483.e5. PubMed
  33. Israelow B, et al. 2020. J Exp Med. 217:00:00. PubMed
  34. Mairhofer D, et al. 2015. J Invest Dermatol. 135: 2785-93. PubMed
  35. Sheikh AA, et al. 2019. Cell Rep. 28:1758. PubMed
  36. Zhu E, et al. 2014. J Immunol. 192:5599. PubMed
  37. Ryu S, et al. 2021. eLife. 0.416666666666667. PubMed
  38. Nance J, et al. 2015. Proc Natl Acad Sci U S A. 112: 13324 - 13329. PubMed
  39. Xu X, et al. 2022. Cells. 11:. PubMed
  40. Aurélien Trompette et al. 2018. Immunity. 48(5):992-1005 . PubMed
RRID
AB_2187123 (BioLegend Cat. No. 104431)
AB_2187123 (BioLegend Cat. No. 104432)

Antigen Details

Structure
Selectin, 95 kD (neutrophils) or 74 kD (lymphocytes)
Distribution

Subsets of B and T cells, monocytes, granulocytes, subset of NK cells

Function
Lymphocyte homing to HEV, rolling on activated endothelium
Ligand/Receptor
CD34, GlyCAM-1, MAdCAM-1
Cell Type
B cells, Granulocytes, Monocytes, Neutrophils, NK cells, T cells, Tregs
Biology Area
Cell Adhesion, Cell Biology, Costimulatory Molecules, Immunology, Innate Immunity
Molecular Family
Adhesion Molecules, CD Molecules
Antigen References

1. Barclay AN, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Kishimoto TK, et al. 1990. P. Natl. Acad. Sci. USA 87:2244.
3. Tedder TF, et al. 1995. J. Exp. Med. 181:2259.

Gene ID
20343 View all products for this Gene ID
UniProt
View information about CD62L on UniProt.org
Go To Top Version: 1    Revision Date: 11/30/2012

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

Login/Register
Forgot your password? Reset Password
Request an Account